Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK Zantac settlement a 'clear win', say brokers
08:18am, Thursday, 10'th Oct 2024
GSK PLC (LSE:GSK, NYSE:GSK) US$2.2 billion settlement for 93% of Zantac litigation cases is almost a best-case scenario short of no payment, according to US broker Jefferies. The broker had pencilled
GSK Stock Jumps as UK Drug Giant Resolves Most US Zantac Lawsuits
07:15am, Thursday, 10'th Oct 2024
GSK (GSK) shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced around claims that its discontinued heartburn medicine Zantac causes
GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside
07:01am, Thursday, 10'th Oct 2024
GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 billion (€2.01bn) to resolve tens of thousands of lawsuits in the US relate
GSK settles vast majority of Zantac claims for $2.2 billion
04:54am, Thursday, 10'th Oct 2024
The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn remedy causes cancer
GSK settles US Zantac lawsuit for $2.2bn
02:54am, Thursday, 10'th Oct 2024
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay up to $2.2 billion to settle around 80,000 US lawsuits concerning its heartburn medication Zantac, generically known as ranitidine. The plaintiffs allege
GSK shares seen opening higher after settlement of 80,000 Zantac lawsuits
02:43am, Thursday, 10'th Oct 2024
Shares of GSK are seen rising 5% according to pre-market indications on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits that claimed its discontinued heartburn
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday
06:39pm, Wednesday, 09'th Oct 2024
In a swarm of lawsuits, the company stood accused of selling a potentially cancer-causing medication.
GSK strikes $2.2bn deal to resolve legal cases in US over heartburn treatment Zantac
02:43pm, Wednesday, 09'th Oct 2024
British drugmaker agrees payment to resolve 80,000 cases alleging cancers were linked to drug known generically as ranitidine
GlaxoSmithKline Reaches $2.2 Billion Settlement in Zantac Lawsuits
01:50pm, Wednesday, 09'th Oct 2024
GlaxoSmithKline (GSK, Financial) has agreed to a substantial settlement in connection with lawsuits related to its Zantac product in U.S. state courts. The company announced that it reached settlement
GSK reaches up to $2.2 billion settlement in Zantac US state court cases
01:00pm, Wednesday, 09'th Oct 2024
GSK said on Wednesday it had reached agreements with ten plaintiff firms, representing 93% of U.S. state court Zantac product liability cases pending against the drugmaker, for up to $2.2 billion.
Here's Why GSK (GSK) is a Strong Value Stock
10:45am, Wednesday, 09'th Oct 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK Reports Sustained Efficacy of RSV Vaccine Amidst Competition from Pfizer and Moderna
11:31am, Tuesday, 08'th Oct 2024
GSK (GSK, Financial) announced that its respiratory syncytial virus (RSV) vaccine has shown protective benefits for three quarters following vaccination. The cumulative efficacy of the vaccine, adjust
RSV Vaccine Demand Drops Sharply in the US, Impacting GSK's Sales
11:10am, Tuesday, 08'th Oct 2024
Recent data indicates a significant drop in the sales of the respiratory syncytial virus (RSV) vaccine in the United States. Major vaccine manufacturers, including GlaxoSmithKline (GSK, Financial), Mo
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
06:50am, Tuesday, 08'th Oct 2024
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people w
GSK RSV shot 43% effective against severe disease in third year
06:47am, Tuesday, 08'th Oct 2024
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the shot.
